- Home
- PODC vs GLTO Comparison
PODC vs GLTO Comparison
Compare PODC & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PODC | GLTO |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5M | 54.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PODC | GLTO |
|---|---|---|
| Price | $2.67 | $22.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 129.4K | 30.1K |
| Earning Date | 02-06-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,957,000.00 | N/A |
| Revenue This Year | $17.27 | N/A |
| Revenue Next Year | $19.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.01 | N/A |
| 52 Week Low | $1.28 | $2.01 |
| 52 Week High | $3.21 | $38.33 |
Technical Indicators
Market Signals| Indicator | PODC | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 43.08 |
| Support Level | $2.57 | $23.85 |
| Resistance Level | $3.21 | $28.40 |
| Average True Range (ATR) | 0.30 | 2.94 |
| MACD | -0.00 | -0.35 |
| Stochastic Oscillator | 37.29 | 4.07 |
Price Performance
Historical ComparisonAbout PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.